# NCT04634877 (NCT04634877)

> Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04634877
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Endometrial Neoplasms
- Interventions: Pembrolizumab; Carboplatin; Paclitaxel; Placebo for pembrolizumab; Docetaxel; Cisplatin; External Beam Radiotherapy (EBRT); Cisplatin (as radiosensitizer); Brachytherapy
- Enrollment: 990
- Primary outcome: Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence
- Primary outcome: Overall Survival (OS)

## Commentary we found

- YouTube: 16
- Podcasts: 13
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct04634877

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04634877", "email": "<work email>"}; the inbox owner confirms by the emailed link.